Imexpharm Corp Asset Resilience Ratio

Latest as of June 2026: 11.76%

Imexpharm Corp asset resilience ratio. Imexpharm Corp (IMP) has an Asset Resilience Ratio of 11.76% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Imexpharm Corp balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₫346.67 Billion

≈ $13.17 Million USD Cash + Short-term Investments

Total Assets

₫2.95 Trillion

≈ $111.96 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio of Imexpharm Corp (2019–2025)

Asset resilience ratio of Imexpharm Corp from 2019 to 2025. This chart shows how Imexpharm Corp's Asset Resilience Ratio has changed over time. See Imexpharm Corp (IMP) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Imexpharm Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Imexpharm Corp asset portfolio.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₫0.00	0%
Short-term Investments	₫346.67 Billion	11.76%
Total Liquid Assets	₫346.67 Billion	11.76%

Asset Resilience Insights

Moderate Liquidity: Imexpharm Corp has 11.76% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Imexpharm Corp Industry Peers by Asset Resilience Ratio

Compare Imexpharm Corp's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Galderma Group N SW:GALD	Drug Manufacturers - Specialty & Generic	3.56%
Enzymatica publ AB ST:ENZY	Drug Manufacturers - Specialty & Generic	22.17%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	9.04%
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	Drug Manufacturers - Specialty & Generic	47.16%
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Walvax BioTech SHE:300142	Drug Manufacturers - Specialty & Generic	2.20%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%

Imexpharm Corp Asset Resilience Ratio by Year (2019–2025)

Imexpharm Corp asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Imexpharm Corp.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	7.62%	₫212.10 Billion ≈ $8.06 Million	₫2.78 Trillion ≈ $105.72 Million	+1.95pp
2024-12-31	5.67%	₫142.00 Billion ≈ $5.40 Million	₫2.50 Trillion ≈ $95.17 Million	+1.78pp
2023-12-31	3.89%	₫93.00 Billion ≈ $3.53 Million	₫2.39 Trillion ≈ $90.90 Million	-5.39pp
2022-12-31	9.28%	₫211.30 Billion ≈ $8.03 Million	₫2.28 Trillion ≈ $86.51 Million	+4.38pp
2021-12-31	4.90%	₫112.45 Billion ≈ $4.27 Million	₫2.29 Trillion ≈ $87.18 Million	+1.87pp
2020-12-31	3.03%	₫63.61 Billion ≈ $2.42 Million	₫2.10 Trillion ≈ $79.65 Million	+2.75pp
2019-12-31	0.28%	₫5.19 Billion ≈ $197.09K	₫1.85 Trillion ≈ $70.18 Million	--

pp = percentage points

About Imexpharm Corp

VN:IMP Vietnam Drug Manufacturers - Specialty & Generic

Market Cap

$209.48 Million

₫5.51 Trillion VND

Market Cap Rank

#16171 Global

#86 in Vietnam

Share Price

₫35800.00

Change (1 day)

+1.13%

52-Week Range

₫35000.00 - ₫56700.00

All Time High

₫97000.00